Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2024-12-09 Major Shareholding Noti…
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G
Major Shareholding Notification
2024-12-09 English
SC 13G
Major Shareholding Notification
2024-12-04 English
SC 13G
Major Shareholding Notification
2024-12-03 English
Director's Dealing 2024
Director's Dealing
2024-11-29 English
SC 13D/A
Major Shareholding Notification
2024-11-26 English
CIDARA THERAPEUTICS, INC. FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 20, 2024, for Cidara Therapeutics, Inc. It reports the entry into a material definitive agreement, specifically a securities purchase agreement for a private placement of common stock and pre-funded warrants, along with a registration rights agreement. The document details the terms of the private placement, the registration rights, and related financial and corporate information. It also includes a press release about the private placement. The content focuses on financing activities and capital raising, not on earnings, management changes, or other report types. Given the detailed disclosure of a financing transaction and capital structure changes, this filing fits the category of Capital/Financing Update (CAP). The document length is substantial (12,700 characters), and it contains substantive details about the financing, not just an announcement or reference to another report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the appropriate classification is CAP with high confidence.
2024-11-26 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.